ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021
Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06217224 (Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma Undergoing High Doses of Methotrexate), which is not on this map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma Undergoing High Doses of Methotrexate
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Is photobiomodulation an effective preventive strategy for oral mucositis in patients with hematologic diseases undergoing chemotherapy?: A systematic review of randomized controlled trials.Lasers in medical science · 2026Pooled it
- Nutritional and Supplemental Interventions for Prevention and Treatment of Oral Mucositis in Pediatric Oncology.Nutrients · 2025Pooled it
- Predictive models for chemotherapy-induced oral mucositis: a systematic review.Frontiers in oncology · 2025Pooled it
- Nutritional prehabilitation in head and neck cancer: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia.European journal of haematology · 2026Article
- Impact of oral mucositis treated by photobiomodulation protocol on the quality of life of pediatric oncology patients with acute lymphoblastic leukemia.Lasers in medical science · 2026Article
- Cause-specific mortality in a population-level cohort of pancreatic cancer patients following chemotherapy: A SEER-based study.Medicine · 2026Article
- Oral Mucositis in Oncopediatric Patients: MTX and MMP-1, MMP-8, MMP-13 Gene Polymorphisms.Oral diseases · 2026Article
- Role of cystatin C in predicting the risk of hypermethotrexemia and kidney injury after high-dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.Annals of hematology · 2026Article
- Use of topical Vitamin E in oral mucositis in patients undergoing oncology treatment. Scoping review.Medicina oral, patologia oral y cirugia bucal · 2026Article
- Determinants of Severe Oral Mucositis Development Despite Photobiomodulation Therapy in Stem Cell Transplant Patients.Dentistry journal · 2025Article
- Risk Factors for Oral Mucositis in Pediatric Oncology Patients Undergoing Chemotherapy: A Prospective Cohort.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Genetics and Epigenetics of Chemoinduced Oral Mucositis in Paediatric Patients with Haematological Malignancies-A Review.Epigenomes · 2025Review
- Potentiality of Curcumin Against Radio-Chemotherapy Induced Oral Mucositis: A Review.Indian journal of surgical oncology · 2025Review
- Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin.Frontiers in oncology · 2025Article
- Clinical Risk Factors for High-Dose Methotrexate-Induced Oral Mucositis Following Individualized Dosing.Cancer medicine · 2024Article
- Chemotherapy-induced oral mucositis: hierarchical analysis of recurrence factors.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2024Article
- Enhancing Standardized Practices for Oral Mucositis Prevention in Pediatric Hematopoietic Stem Cell Transplantation: A Best Practice Implementation Project.Risk management and healthcare policy · 2024Article
- TNF-α promoter hypomethylation is frequent in oncopediatric patients who recovered from mucositis.Brazilian oral research · 2024Observational
- Nursing care approaches to oral mucositis in pediatric oncology clinics: a cross-sectional study from Türkiye.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo investigate the incidence and risk factors for oral mucositis (OM) in patients with childhood cancer undergoing chemotherapy.
methodsEight hundred and twenty-nine cycles of chemotherapy were evaluated in 112 patients with childhood cancer undergoing chemotherapy. Chemotherapy protocol, hematological, hepatic, and renal function parameters were collected and compared to presence and severity of OM, as graded by the World Health Organization (WHO) scale. Patients received counseling on oral hygiene and those who presented with OM (grade ≥1) received photobiomodulation therapy (PBMT).
resultsAge ranged from 0 to 17 years (mean/SD, 8.58 ± 5.05) and fifty-one patients (45.54%) were females. The most common baseline diseases were leukemia (51%) followed by sarcomas (23%) and lymphomas (18%). Eight hundred and twenty-nine cycles of chemotherapy were evaluated, and OM was diagnosed in 527 cycles (63.57%). Higher incidence and severity of OM was observed in protocols using high-dose methotrexate (MTX-HD), MTX-HD cyclophosphamide/doxorubicin combination, and MTX-HD combined with cyclophosphamide (p <0.001). Patients with severe OM had lower levels of leukocytes (p = 0.003), hemoglobin (p = 0.005), platelets (p = 0.034), and higher levels of total bilirubin (p = 0.027), alanine aminotransferase (ALT) (p = 0.001), and creatinine (p = 0.007).
conclusionThe study contributes to the elucidation of the risk factors for OM in pediatric cancer patients. Chemotherapy protocols using MTX-HD, MTX-HD associated with doxorubicin and cyclophosphamide, and MTX-HD and cyclophosphamide a have higher incidence of severe grades of OM. Other toxicities such as hematological, hepatic, and renal also developed in patients with OM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.